International journal of geriatric psychiatry
-
Int J Geriatr Psychiatry · Sep 2012
Letter Randomized Controlled TrialRivastigmine in the treatment of postoperative delirium: a pilot clinical trial.
-
Int J Geriatr Psychiatry · Sep 2012
Randomized Controlled TrialMemantine for late-life depression and apathy after a disabling medical event: a 12-week, double-blind placebo-controlled pilot study.
Preclinical data suggests that memantine, a noncompetitive glutamate N-methyl- D-aspartate-receptor blocker used for the treatment of moderate to severe Alzheimer's disease, could reduce depressive and amotivated behavior occurring in the context of psychosocial stress. Therefore, we examined whether memantine could reduce depressive symptoms and amotivation manifesting in older adults after a disabling medical event, thereby improving their functional recovery. ⋯ Memantine was not associated with superior affective or functional outcome compared with placebo in medically rehabilitating older adults with depressive and apathy symptoms.
-
Int J Geriatr Psychiatry · Mar 2012
Randomized Controlled TrialTolerability of extended-release quetiapine fumarate compared with immediate-release quetiapine fumarate in older patients with Alzheimer's disease with symptoms of psychosis and/or agitation: a randomised, double-blind, parallel-group study.
The objective of this study was to assess the safety and tolerability of extended-release quetiapine fumarate (quetiapine XR) compared with quetiapine immediate-release (quetiapine IR) in older patients with Alzheimer's disease with symptoms of psychosis and/or agitation. ⋯ Quetiapine XR dosed up to 300 mg/day was generally well tolerated, with a similar profile to that of quetiapine IR.
-
Int J Geriatr Psychiatry · Dec 2011
Randomized Controlled Trial Multicenter StudyRivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
The cholinesterase inhibitor rivastigmine is approved for the symptomatic treatment of mild to moderate Alzheimer's disease (AD). This exploratory, hypothesis-forming analysis assessed response to rivastigmine according to severity of dementia at baseline. ⋯ Rivastigmine benefits AD patients across dementia stages. Similar to previous cholinesterase inhibitor studies, greatest treatment effects with rivastigmine patch and capsule were seen in patients with more advanced dementia, most likely driven by greater placebo decline in this population.
-
Int J Geriatr Psychiatry · Jul 2011
Randomized Controlled Trial Multicenter StudyMelatonin decreases delirium in elderly patients: a randomized, placebo-controlled trial.
Disturbance in the metabolism of tryptophan and tryptophan-derived compounds (e.g., melatonin) may have a role in the pathogenesis of delirium. ⋯ Exogenous low dose melatonin administered nightly to elderly patients admitted to acute care may represent a potential protective agent against delirium.